Therefore, the development of new therapeutic approaches is particularly urgent in pancreatic tumors.
One of the most promising approaches to emerge from the improved understanding of cancer at the molecular level is the possibility of using gene therapy to selectively target and destroy tumor cells. 3 It has became clear that tumorigenesis is driven by alterations in genes that control cell growth or cell death. 4, 5 Despite the multiplicity of these lesions within a cancer cell, the correction of a single critical genetic lesion may be sufficient to abrogate tumorigenicity in human cancer cells if the function restored succeeds in the reestablishment of growth control to an extent that would eventually lead to selective tumor cell death by apoptosis. 6 The p53 tumor suppressor gene is the most frequent target for genetic alterations in human cancer.
7 p53 protein has a central role in the cellular response to DNA damage. 8, 9 Induction of p53 might lead to growth arrest and/or to apoptosis depending upon p53 levels, cell type, and the cellular environment. 10, 11 It is not fully understood what functions of p53 are required for cell cycle arrest or apoptosis. The role of p53 in the G 1 checkpoint, where it induces growth arrest mediated by the cyclin-dependent kinase inhibitor (CKI) p21
Cip1 , is well established. 12, 13 Several authors have reported the role of the CKI p16
Ink4a in the control of this checkpoint and postulate a cooperation between p16 and p53 that leads to a more efficient induction of premature senescence or apoptosis. 14, 15 p53 has also been implicated in a G 2 /M checkpoint. 16 -19 Controversial results have been published regarding the function of p53 in this checkpoint. Expression of p53 has been associated with growth arrest in the G 2 /M phase of the cell cycle, 16, 17 whereas other authors report a positive role for p53 in G 2 exit after ␥-irradiation or treatment with the DNA topoisomerase II inhibitor etoposide. 18, 19 It is less clear how p53 induces apoptosis. Recently, Polyak et al have suggested a model for p53 apoptosis on the basis of the marked increase in several transcripts in p53-expressing cells. 20 Tumor suppressor gene therapy requires efficient systems of gene delivery. Adenoviral vectors have many advantages over other viral and nonviral vectors in that high titers of virus can be obtained and the virus is stable and easy to handle. 21 Adenoviruses (Ads) have been successfully assayed in vitro and have been administered safely in vivo to several organs, leading to efficient gene delivery in both systems. [22] [23] [24] [25] [26] [27] In this study, a recombinant replication-defective Ad (Ad5CMV-p53) was used to transfer wild-type (wt) p53 cDNA into four human pancreatic tumor cell lines. The exogenous gene was delivered efficiently, and the restoration of p53 function significantly inhibited the growth in the four cell lines, more strongly in mutant p53 cells. An arrest in the G 1 phase of the cell cycle was observed in all cell lines, but the induction of apoptosis was dependent upon the genetic background of tumor cells. The overall results may have important implications for treatments aiming to restore p53 function in tumor cells.
MATERIALS AND METHODS

Construction and preparation of recombinant Ads (rAds)
p53 and ␤-galactosidase cDNA were fused to a simian virus 40 polyadenylation signal and cloned downstream of the cytomegalovirus promoter in a pACCMVpLpA plasmid. rAds were generated by cotransfection of this plasmid with pJM17 into subconfluent cultures of 293 cells using a modified calcium phosphate precipitation technique. Individual viral plaques were isolated and amplified in 293 cells, and rAd plaques containing human p53 cDNA and ␤-galactosidase cDNA were identified by polymerase chain reaction amplification and restriction enzyme digestion. Virus without insert (Ad-control) was generated in the same way. Ad5RSV-p16 was a kind gift of Dr. J. Fueyo (M.D. Anderson Cancer Center, Houston, Tex). Viral clones were propagated in 293 cells and recovered after 48 hours by three cycles of freezing and thawing. Titers were determined by plaque assay on 293 cells.
Cell lines and culture conditions: Infection conditions
The NP-9, NP-18, NP-29, and NP-31 cell lines were derived from human pancreatic adenocarcinomas that had been perpetuated as xenografts in nude mice. 28 NP-9 and NP-29 were maintained in Dulbecco's modified Eagle's medium/F12 medium (1:1) and NP-18 and NP-31 were maintained in RPMI 1640 (both supplemented with 10% fetal bovine serum) in a humidified atmosphere containing 5% CO 2 at 37°C. The status of the p53, p21, and p16 genes in these cell lines is summarized in Table 1 .
Cells were plated and subsequently infected 24 hours later with Ad for 12 hours in serum-free medium at 37°C. Optimal concentrations of virus causing expression in Ͼ90% of cells, without visible toxic effects, were determined by infection with Ad5CMV-lacZ and subsequent staining with 5-bromo-4-chloro-3-indolyl ␤-D-galactoside. In the experiments carried out with two viral vectors, sequential incubations separated by 48 hours were performed.
Cell growth rate determination
Pancreatic cell lines were seeded (10,000 cells/well) in 24-well culture plates. The cells were infected with either Ad5CMV-p53 or Ad-control. Serum-free culture medium was used for mock infection. Quadruplicate dishes of each treatment were counted at regular intervals until 8 days postinfection in an autoanalyzer Multisizer (Coulter, Hialeah, Fla).
Immunocytochemistry assay
After 36 hours, the infected cell monolayers were fixed in methanol (Ϫ20°C) and treated with 3% H 2 O 2 for 5 minutes. Immunodetection was performed after blocking with phosphate-buffered saline/bovine serum albumin 3% and by using a monoclonal antibody (Ab) against p53 (Ab-2), Oncogene Research Products, Cambridge, Mass) as the primary Ab. Mouse immunoglobulin G (IgG) was used as a control. The secondary Ab was a horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Dako, Carpinteria, Calif). Peroxidase activity was determined with diaminobenzidine/H 2 O 2 after incubation at 37°C for 30 minutes. The cells were counterstained with Harris hematoxylin.
Western blot analysis
Total cell lysates obtained by incubation in RIPA buffer (150 mM NaCl, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 20 mM ethylenediaminetetraacetic acid, and 1% Igepal CA-630 in 50 mM tris(hydroxymethyl)aminomethane) (pH 7.4)) for 1 hour were sonicated at 50 W for three cycles of 30 seconds. After centrifugation at 14,000 ϫ g, supernatant proteins (25 g/lane determined by bicinchoninic acid protein assay) (Pierce, Rockford, Ill) were electrophoretically separated on 10% polyacrylamide-sodium dodecyl sulfate gel and transferred to nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany). Membranes were developed according to an enhanced chemiluminescence protocol (Amersham, Arlington Heights, Ill). Monoclonal Ab against human p53 Ab-2 and polyclonal Ab (pAb) against p21 (Santa Cruz Biotechnology, Santa Cruz, Calif) and actin (Sigma, St. Louis, Mo) were used as primary Abs; HRPconjugated anti-mouse IgG, HRP-conjugated anti-goat IgG, and HRP-conjugated anti-rabbit IgG (Sigma) were used as secondary Abs. Relative quantities of p53 and p21 were determined by using a scanner (SNAP SCAN 600-Agfa, Geraert Morstel, Belgium) and Phoretix 1D Advanced software (Non Linear Dynamics, Newcastle, UK) for data densitometric analysis.
Cell cycle analysis
All cell cycle distribution measurements were performed on an Epics-XL flow cytometer (Coulter) equipped with an aircooled argon ion laser to give 488 nm light. Triplicates of cell cultures were incubated in etoposide at a final concentration of *CGC, arginine; CAC, histidine; ATG, methionine; GTG, valine. †An abnormal SSCP pattern was evidenced in multiple experiments; no mutation was detected by direct sequencing and/or sequencing of the polymerase chain reaction product.
‡Homozygous deletion 2 M for 24 hours before or after infection with rAds. Cells were harvested and stained in tris(hydroxymethyl)aminomethane-buffered saline containing propidium iodide (PI) (50 g/ mL), ribonuclease A (10 g/mL), and Igepal CA-630 (0.1%) for 1 hour at 4°C. Data from Ն10,000 cells were collected andanalyzed using Multicycle software (Phoenix Flow Systems, San Diego, Calif).
Apoptosis assays
Chromatin structure was visualized by staining cells with Hoechst 33342 (5 g/mL) for 1 hour at 37°C at 36 hours after infection with rAds. For Hoechst 33342 pulse labeling, 1 ϫ 10 6 cells were trypsinized and resuspended in 1 mL of medium supplemented with 10% fetal bovine serum. Hoechst 33342 was added to a final concentration of 1 g/mL, and cells were maintained at 37°C for 30 seconds. Uptake of the dye combined with cell size determination allows calculation of the percentage of apoptotic cells. 29 Triplicates of each sample were analyzed with an Elite flow cytometer using the 350-nm line of the argon ion laser. Elite software was used for data analysis.
RESULTS
Efficiency of adenoviral infection in pancreatic cancer cells and analysis of exogenous p53 expression
Pancreatic cell lines are efficiently infected by Ad, because all four cell lines used in this work (NP-9, NP-18, NP-29, and NP-31) presented efficiencies of transduction that were Ͼ90% when they were infected with Ad5CMV-lacZ reporter virus at concentrations as low as 10 multiplicities of infection (m.o.i.) (data not shown). p53 expression was tested by immunocytochemistry and Western blotting in the four cell lines after infection with Ad5CMV-p53. For immunocytochemical assay, the expression and the localization of the exogenous protein were evaluated 36 hours after the viral infection. The immunocytochemical pattern in virus-infected cells revealed a characteristic staining of p53 protein in the nucleus that was not seen in control cells (Fig 1, A and  B) . Cells expressing exogenous p53 also had a larger mean diameter than noninfected cells (Fig 1, C and D) .
Cellular extracts of control and Ad5CMV-p53-transduced cells were prepared 36 hours after viral infection to evaluate p53 expression by Western blot. p53 levels were markedly increased in all infected cells (Fig 2A) . p21 Cip1 protein has been reported as one of the most important transcriptional targets of p53. 12, 13 When its levels were analyzed, the expression of p21
Cip1 was higher in transduced cells than in controls (Fig 2A) , demonstrating that the newly expressed p53 protein was transcriptionally functional.
Expression of the transgene was maintained in the four cell lines from day 1 to at least day 8 and was maximal at 36 -60 hours. Later on, p53 levels decreased slowly, probably due to the outgrowth of noninfected cells together with the episomal localization of viral DNA. A time course of p53 expression in NP-9-infected cells is shown in Figure 2B .
Effects of exogenous p53 on cell cycle progression and apoptosis Various viral concentrations were assayed to find a dose that would cause a p53-mediated decrease in cell number without significant toxic effects. Optimal results were obtained with doses ranging from 40 to 80 m.o.i. (data not shown). When cell lines were infected with Ad5CMV-p53 (50 m.o.i.) and counted on alternate days postinfection (Fig 3) , all four showed a significant decrease in cell number. The growth curves obtained when cells were infected with Ad-control supported the possibility that the inhibitions observed were a consequence of the increased expression of wt p53. In the cultures infected with Ad5CMV-p53, the numbers of cells at 4 days postinfection were 3.8%, 17.5%, and 7.2% in mutant p53 cell lines NP-18, NP-31, and NP-9, respectively, and 30.1% in the wt p53 NP-29 cells, with respect to the controls (Fig 3) . These differences suggest that the effect of the expression of the transduced protein on the growth depended upon the p53 status of the cells. To determine the mechanism by which p53 overexpression inhibits growth, cell cycle profiles and apoptosis were analyzed. Flow cytometric profiles obtained at 36 hours after viral infections showed that the expression of exogenous p53 protein led to a significant G 1 arrest in all cell lines (Fig 4) . These profiles indicate that the decreases in cell number are due, at least in part, to an arrest in the G 1 phase of the cycle.
Apoptosis was analyzed in control cultures and in Ad5CMV-p53-transduced cells by incubation with the vital DNA dye Hoechst 33342. Characteristic morphological patterns with fragmented DNA in the nucleus and the appearance of apoptotic bodies were not present in control NP-18 cells but were evident in transduced NP-18 cells at 36 hours postinfection (Fig 5) . To quantify the percentage of apoptotic cells in cultures, Hoechst 33342 pulse-labeling experiments were performed (Table 2). The results revealed that the difference in the percentage of apoptotic cells between control and infected cultures in NP-29 cells was negligible (6.8 Ϯ 2.2% vs. 8.3 Ϯ 0.8%), indicating that the expression of exogenous p53 did not induce apoptosis in this wt p53 cell line. In contrast, a marked increase in the number of apoptotic cells was observed in the Ad5CMV-p53-transduced cultures of mutant p53 cell lines with respect to control cells. However, the percentages of apoptotic cells for the cell lines were different (1.0 Ϯ 0.3% vs. 11.0 Ϯ 2.1% of apoptotic cells in NP-9; 6.9 Ϯ 0.5% vs. 51.0 Ϯ 2.4% in NP-18).
To determine whether the significantly higher apoptotic level achieved by the p53-transduced NP-18 cell line (Table 2) clearly indicate a significant increase in apoptotic level due to the presence of wt p16 in the NP-9 cell line.
Effects of exogenous p53 on cell cycle and apoptosis after etoposide treatment
We have also determined the effects on cell cycle and apoptosis induced by exogenous p53 expression in response to DNA damage produced by the DNA topoisomerase II inhibitor, etoposide.
Cultures of all cell lines were infected with Ad5CMV-p53 or maintained in culture medium and subsequently treated for 24 hours with 2 M of etoposide. The cell cycle profiles of the noninfected cells showed important differences in response to etoposide treatment. The mutant p53 cells (NP-9, NP-18, and NP-31) showed a clear arrest in G 2 . In contrast, the wt p53 cells (NP-29) did not show arrest in G 2 in response to the same treatment (Fig 6A) . In this cell line, treatment with increasing concentrations of the drug induced increases in the levels of the endogenous p53 protein (Fig 7) . In Ad5CMV-p53-transduced mutant p53 cells, etoposide did not induce the clear G 2 arrest that was detectable in untransduced cells, whereas no significant differences were observed between transduced and untransduced NP-29 cells (Fig 6A) .
Identical etoposide treatments were performed before introduction of the wt p53 gene. The changes observed in the cell cycle profiles of mutant p53 cells indicate that G 2 blocking progressed toward endoreduplication processes in the course of 3 days posttreatment; these processes were abolished when wt p53 was introduced (Fig 6B) .
No significant increases in apoptosis were observed in either control or Ad5CMV-p53-infected NP-29 cells, in contrast to mutant p53 cells (Table 2 ). This result corroborates the inability of NP-29 to die by apoptosis in response to the overexpression of wt p53.
DISCUSSION
Only a few studies on wt p53 gene replacement in pancreatic cancer have been reported, and the results are controversial. 30 -32 Thus, Kimura et al did not detect apoptosis after wt p53 transduction either in vitro or in vivo. 31 In contrast, very recently Lang et al reported multiple phenotypic changes in one pancreatic cell line (Panc-1) as a consequence of wt p53 transduction. 32 The availability of new pancreatic cell lines with marked differences in their p53 and p16 gene status allows us to study the influence of the genetic background of the target cell on the impact of p53 overexpression. With the aid of a recombinant reporter gene Ad, Ad5CMV-lacZ, we determined the ability of Ad to infect pancreatic tumor cells. Remarkably, the transduction efficiency achieved was very high, which makes possible successful Ad-mediated p53 transfer without the toxicity associated with high virus concentrations. When the p53 gene was delivered to pancreatic cell lines, the expressed p53 proved to be functional. First, immunocytochemical analysis revealed that the newly expressed wt p53 is located mainly in the nucleus, like the endogenous protein. Marked morphological changes were observed, providing the first evidence that exogenous p53 is expressed in a functional way. Western blot analysis demonstrated that expression of the wt p53 protein was significantly increased in all infected cells and maintained long enough to achieve notorious effects on cell proliferation. The growth of the four cell lines when transduced with Ad5CMV-p53 was significantly lower than that of cells transduced with control Ad, indicating that this effect was due to the overexpression of p53. The high expression of the newly transduced protein had different effects on the growth of the infected cell lines, depending upon the p53 status of the cells. The wt p53 cells showed less inhibition of proliferation than the mutant p53 cells, as described in some types of tumor cells 22, 33 but not in others. 34 The mechanism by which wt p53 protein inhibits growth may be related to arrest of the cell cycle or to apoptosis. 9, 10 The mechanism underlying the cytocidal effect induced by p53 appeared to be dependent upon the cell types and the availability of downstream effectors. 20, 35 When the cell cycle profile was analyzed, all cell lines experienced arrest in the G 1 cell cycle phase, which is consistent with the increase observed in p21
Cip1 expression as assessed by Western blot. These observations clearly indicate that exogenous p53 expression can activate the transcription of this CKI, which contributes significantly to drive the effects of p53 on the cell cycle, 12, 13 and consequently, to growth inhibition. However, there was great variation in the degree of apoptosis induced by the overexpression of exogenous wt p53 in the four cell lines. NP-29, with functional endogenous p53, did not apoptotize when exogenous wt p53 was expressed. This may explain the low level of inhibition of this cell line. The lack of response to overexpression of p53 is consistent with the fact that p53 is still functional in NP-29 cells, thus indicating that the altered factors responsible for the tumoral behavior of these cells must be located downstream of the p53-dependent apoptotic pathway. In our cells, no significant differences in bax or bcl-2 were found when their levels of expression were analyzed by Western blotting in nontransduced cell extracts of the four cell lines (data not shown). Recently, it has been postulated that one of the main functions of the CKI p21
Cip1 is to modulate the timing and intensity of the p53 apoptotic signals. 36 The ratios between p21 and p53 concentrations were very similar, ruling out the possibility that this factor was responsible for the lack of apoptosis in NP-29 cells.
The differences observed between different mutant p53 cell lines could be related to alterations in other elements involved in cell cycle checkpoints. 37, 38 Sandig et al have recently reported that the Ad-mediated overexpression of wt p16 collaborates very efficiently with p53 in the induction of apoptosis in human hepatocellular and breast carcinoma cells.
14 Our results with p53 suggested that the endogenous levels of wt p16 could condition apoptosis in response to exogenous p53. Indeed, the wt p16 cell line (NP-18) showed a significantly higher apoptotic level (51% of apoptotic cells) than the NP-9 cell line (11% of apoptotic cells), which presents a deleted p16 gene. The increases in apoptotic level observed when both p16 and p53 genes are introduced in NP-9 cells (46.5% of apoptotic cells) support this contribution. Although several hypotheses have been advanced as to how the actions of p16 render tumor cells more susceptible to apoptotic stimuli, 14, 39 the current knowledge of apoptosis-controlling pathways is insufficient to fully explain the synergism observed between the actions of p16 and p53.
It is well established that p53 is a key factor in the connection between DNA damage and the cellular apparatus responsible for death by apoptosis. 40, 41 Etoposide increases the apoptotic response and may cause G 2 blocking depending upon p53 status, thus throwing light on this connection. In our cell lines, the expression of wt p53 prevented the accumulation of cells in G 2 provoked by etoposide, irrespective of the endogenous or exogenous origin of wt p53. The abrogation of G 2 blocking when the p53 function is introduced before the drug treatment could indicate that wt p53 can override the etoposide-induced blocking of G 2 , as demonstrated by other authors in different cell types. 19 However, the possibility that p53 G 1 arrest predominates over G 2 arrest in wt p53-expressing cells cannot be ruled out. The results obtained when p53 is introduced after the etoposide treatments support the first hypothesis, indicating that p53 is allowing DNA-damaged cells to exit from G 2 .
The Hoechst pulse experiments performed in control and infected NP-9 and NP-18 cells indicate that a significant increase in apoptosis accompanies the abrogation of G 2 block achieved by the combined treatments in mutant p53 cell lines. This behavior may be explained if cell cycle deregulation is considered as part of the common pathway of apoptosis, and checkpoints may be actively bypassed after the cell is committed to die.
On the contrary, although the level of endogenous p53 in NP-29 rose as a consequence of etoposide treatment and G 2 block was not observed, no variations in apoptotic rate were observed in either control or infected cultures, reinforcing the suggestion that this wt p53 tumor cell line either lacks other downstream functions in the p53-dependent apoptosis pathway or that these functions are altered.
The overall results indicate that the status of tumor suppressor genes, such as p16 and p53, in pancreatic tumor cells and the possibility of the restoration of their function may drastically modify their response to different treatments. The expression of p53 alone may have important cytotoxic activity toward tumors that conserve unaltered the elements necessary to develop the p53 function in G 1 checkpoint and apoptosis processes. Preliminary results obtained in our laboratory show that p53 transduction in cells previously implanted into the subcutaneous tissue of nude mice reduces tumor growth in vivo. Taken together, our data may have important implications for gene therapy with p53 or other treatments aimed at restoring p53 function in tumor cells to induce apoptosis.
